China Shineway Pharmaceutical Group Limited, commonly referred to as Shineway Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1997, the company has made significant strides in the development and manufacturing of traditional Chinese medicine and modern pharmaceuticals, with a strong operational presence across Asia and beyond. Shineway Pharmaceutical is renowned for its core products, including herbal medicines and innovative therapeutic solutions, which are distinguished by their quality and efficacy. The company has achieved notable milestones, such as receiving various certifications for its manufacturing processes, solidifying its reputation in the market. With a commitment to research and development, Shineway continues to enhance its product offerings, positioning itself as a leader in the pharmaceutical sector and contributing to the global healthcare landscape.
How does China Shineway Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
China Shineway Pharmaceutical's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, China Shineway Pharmaceutical, headquartered in CN, reported total carbon emissions of approximately 141,380,020 kg CO2e. This figure includes 87,499,000 kg CO2e from Scope 1 emissions, 30,190,000 kg CO2e from Scope 2, and 23,691,000 kg CO2e from Scope 3 emissions. The total emissions for Scope 1 and 2 combined were about 117,689,510 kg CO2e. The company has not disclosed specific reduction targets or initiatives as part of its climate commitments. However, it is noted that emissions data is cascaded from its parent company, China Shineway Pharmaceutical Group Limited, which may influence its overall climate strategy. For 2021, the emissions were reported at 117,794,000 kg CO2e globally, with similar scopes of emissions as in 2022. The trend indicates a consistent level of emissions without significant reduction targets outlined in the available data. China Shineway Pharmaceutical's commitment to addressing climate change remains unclear, as there are no specific pledges or targets reported in the current data. The company operates within an industry context that increasingly prioritises sustainability and emissions reduction, yet it has not publicly committed to any specific initiatives or frameworks such as the Science Based Targets initiative (SBTi).
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Scope 1 | 117,620,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 8,186,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 27,604,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
China Shineway Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
